Back to Feed
ClinicalTrials.gov|Clinical Trial
Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
University College, London
Abstract
MAGNETO is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and teenagers aged 1-16 years with relapsed or refractory neuroblastoma. The study will assess the feasibility of generating the ATIMP (GD2 CAR T cells) and the safety of administering the ATIMP in patients with relapsed or refractory neuroblastoma. Phase: PHASE1 Status: ACTIVE_NOT_RECRUITING Conditions: Neuroblastoma Interventions: GD2 CAR T cells
Keywords
Neuroblastoma